Maryland Diabetes Drug Improper Marketing Lawsuit
GlaxoSmithKline agreed to pay the State of Maryland $15 million to resolve allegations that the company engaged in improper marketing of the prescription diabetes drugs Avandia, Avandamet, and Avandaryl. The lawsuit alleged that GlaxoSmithKline falsely touted the drugs as superior to other diabetes medications. The lawsuit also alleged that the company withheld data showing that its drugs dramatically increase the risk of heart attack and other serious adverse effects.
- Misconduct Type
- Enforcement Agency
- Contracting Party
- Court Type
- Date of Settlement Announcement